American Society of Hematology, 2025 (ASH) 7 - 9 December 2025

Mim8 prophylaxis in adults and adolescents with Hemophilia A: 52-week efficacy and safety outcomes from the Phase 3 FRONTIER2 study

Authors :

Steven Lentz¹, Aby Abraham², Cihan Ay³, Anthony Chan⁴, Víctor Jiménez-Yuste⁵, Johannes Oldenburg⁶, Maria Elisa Mancuso^{7, 8}, Johnny Mahlangu⁹, Tadashi Matsushita¹⁰, Lize van Vulpen¹¹, Renchi Yang¹², Amalie Rhode Høgh Nielsen¹³, Ilgiz Rakhmatullin¹³, Pratima Chowdary¹⁴

Affiliations

View Details Hide Details

PDF default button label

Keywords

Haemophilia

Congress oral presentation

Mim8

Search Science Hub

Are you a healthcare professional?

Mim8 prophylaxis in adults and adolescents with Hemophilia A: 52-week efficacy and safety outcomes from the Phase 3 FRONTIER2 study